Calidi Biotherapeutics, Inc. financial data

Symbol
CLDI on NYSE, CLDWW on OTC
Location
4475 Executive Drive, Suite 200, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 8, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 94.1 % +136%
Return On Equity -5.16K % -2078%
Return On Assets -176 % +19.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.43M shares -57.6%
Common Stock, Shares, Outstanding 2.88M shares -55.5%
Common Stock, Value, Issued 3K USD -25%
Weighted Average Number of Shares Outstanding, Basic 27.1K shares +662%
Weighted Average Number of Shares Outstanding, Diluted 27.1K shares +662%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 8.99M USD -25.9%
Operating Income (Loss) -20M USD +32.4%
Nonoperating Income (Expense) -53K USD -101%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -20M USD +13.8%
Income Tax Expense (Benefit) 9K USD -55%
Net Income (Loss) Attributable to Parent -19.9M USD +14.3%
Earnings Per Share, Basic 13 USD/shares +88.1%
Earnings Per Share, Diluted 13 USD/shares +88.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 6.05M USD +272%
Property, Plant and Equipment, Net 929K USD -12.4%
Operating Lease, Right-of-Use Asset 2.33M USD -33.7%
Other Assets, Noncurrent 40K USD -82.4%
Assets 9.35M USD +45.4%
Liabilities, Current 5.35M USD -59%
Operating Lease, Liability, Noncurrent 993K USD -59.7%
Liabilities 7.28M USD -60%
Accumulated Other Comprehensive Income (Loss), Net of Tax -13K USD +51.9%
Retained Earnings (Accumulated Deficit) -132M USD -17.6%
Stockholders' Equity Attributable to Parent 1.76M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 2.08M USD
Liabilities and Equity 9.35M USD +45.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.13M USD -86.1%
Net Cash Provided by (Used in) Financing Activities 8.11M USD +169%
Net Cash Provided by (Used in) Investing Activities -7K USD -40%
Common Stock, Shares Authorized 330M shares 0%
Common Stock, Shares, Issued 2.88M shares -55.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 970K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.38M USD +410%
Interest Paid, Excluding Capitalized Interest, Operating Activities 639K USD +2563%
Operating Lease, Liability 2.3M USD -35.8%
Depreciation 391K USD -2.49%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -19.8M USD +14.7%
Lessee, Operating Lease, Liability, to be Paid 2.55M USD -39%
Property, Plant and Equipment, Gross 2.54M USD +13%
Operating Lease, Liability, Current 1.3M USD +16.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 295K USD -80.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.51M USD +3.28%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 250K USD -58.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2K USD -99.6%
Operating Lease, Payments 362K USD +3.73%
Additional Paid in Capital 134M USD +33.1%
Share-based Payment Arrangement, Expense 2.45M USD -37.8%